Laurus Labs performed well considering goods and services tax (GST) and such other disruptions. It's the R&D focus of the company that perhaps stands out.
In an interview to CNBC-TV18, Satyanarayana Chava, Founder & CEO of Laurus Labs spoke about the results and his outlook for the company.
Q1 sales increased by around 16 percent and EBITDA also increased by 20 percent, he said.
He expects to get 2 abbreviated new drug application (ANDA) approvals in FY18.
Laurus Labs is only into active pharmaceutical ingredients (API) for now. It will start selling finished drugs by end of this financial year.
Chava expect to sell formulations that will aid margins.
Unit-1 and Unit-3 inspections will begin next week by the US Food and Drug Administration (US FDA), he added.Watch accompanying video for more details.